LYTIX BIOPHARMA AS revenue breakdown overview

LYTIX BIOPHARMA AS revenue for the last year amounted to 10.06 M NOK, the most of which — 3.99 M NOK — came from its highest performing source at the moment, Oncolytic Peptides, the year earlier bringing 17.27 M NOK. The greatest contribution to the revenue figure was made by United States — last year it brought LYTIX BIOPHARMA AS 3.99 M NOK, and the year before that — 11.03 M NOK.